Israel
-
Israel printed a new 10 year bond and a tap of 2043s on Wednesday with only a small new issue concession and some of the biggest books seen so far this year for a CEEMEA bond.
-
Israel has tightened price guidance on its 2043s tap and new 10 year bond, both in dollars, in the hope of printing the deal later on Wednesday.
-
Israel has embarked on a US roadshow for a dollar bond, using the same three lead managers as it has done for its last two Eurobonds.
-
Teva Pharmaceutical Industries “just scraped home” with very tight pricing on the $33.75bn loan it signed on Monday. Only around half the banks invited participated because margins were so tight, said a banker close to the deal. -
Teva, the New York-listed Israeli pharmaceutical company, has completed and signed $33.75bn of loans for its acquisition of Allergan Generics.
-
Teva, the New York-listed Israeli pharmaceutical company, held a meeting with banks on Wednesday for the syndication of $33.75bn of loans to buy generic drug business Allergan Generics.
-
Teva, the Israeli pharmaceutical company, will hold a meeting with banks on Wednesday for the syndication of $33.75bn of loans it is using to buy generic drug business Allergan Generics.
-
Israeli pharmaceutical company Teva has 15 days to raise $33.75bn of funds to buy US firm Allergan's generics business.
